Fig. 4: Time-to-event plot showing the time between treatment initiation and the development of specific irAEs.

The comparisons between renal cancer patients receiving chemotherapy with A pembrolizumab, B nivolumab, and C all immune checkpoint inhibitors are shown in three separate columns. We examined 56 irAEs separately, with p-values corrected by the Benjamini–Hochberg procedure. Adjusted p-values < 0.05 were highlighted in red. Renal cancer patients receiving nivolumab have higher risks of developing hypothyroidism and thyrotoxicosis, but those receiving pembrolizumab did not have a significantly increased risk. Each tick represents 50 censored patients. The curves are truncated in the 15th month after treatment initiation for better visualization. The numbers at the bottom panel indicate the number of remaining patients at 0, 3, 6, 9, 12, and 15 months after treatment initiation. Plots for all other cancer types can be found in Supplementary Fig. 2; plots for a longer time horizon can be found in Supplementary Fig. 4.